-

GeneDx to Participate in Fall Investor Conferences

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences this fall:

  • UBS Genomic Medicine Summit – August 13-14, 2024
    Dana Point, California
    Future of Genetic Testing - Babies and Beyond Panel on Wednesday, August 14 at 8:00 a.m. PT
  • Morgan Stanley Healthcare Conference - September 4-6, 2024
    New York, New York
  • Wells Fargo Healthcare Conference - September 4-6, 2024
    Boston, Massachusetts
    Fireside chat on Thursday, September 5 at 8:45 a.m. ET
  • Jefferies London Healthcare Conference - November 19-21, 2024
    London, England

Live and archived webcasts of select presentations will be available on the “Events” section of the GeneDx investor relations website at ir.genedx.com/news-events/events.

About GeneDx

At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It all starts with a single test. For more information, please visit genedx.com and connect with us on LinkedIn, X, Facebook, and Instagram.

Contacts

Investor Relations Contact:
investors@GeneDx.com

Media Contact:
press@GeneDx.com

GeneDx

NASDAQ:WGS

Release Summary
GeneDx (Nasdaq: WGS) today announced that company management will participate in upcoming investor conferences this fall.
Release Versions

Contacts

Investor Relations Contact:
investors@GeneDx.com

Media Contact:
press@GeneDx.com

More News From GeneDx

GeneDx to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced that company management will participate in the upcoming TD Cowen and Barclays healthcare investor conferences....

INSERTING and REPLACING GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2025....

TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List of the World’s Most Influential Leaders in Health

GAITHERSBURG, Md.--(BUSINESS WIRE)--TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List...
Back to Newsroom